Trial Profile
Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2019
Price :
$35
*
At a glance
- Drugs Eltrapuldencel-T (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms DCVaccineMel
- 04 Jun 2019 Results assessing survival for melanoma patients who were treated with patient specific vaccines by using data from two phase II studies presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2019 Pooled data from this and other trial (NCT00436930) were presented in an AiVita Biomedical Media Release.
- 03 Jun 2019 According to an AiVita Biomedical media release, pooled data from this and other trial (NCT00436930) presented at the Annual Meeting of the American Society of Clinical Oncology 2019.